ChronoScale Corporation Common Stock (NASDAQ:CHRN) Research Coverage Started at Northland Securities

Northland Securities began coverage on shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN) in a research note issued to investors on Friday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $32.00 price objective on the stock.

Separately, Weiss Ratings raised ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, August 24th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $19.00.

ChronoScale Corporation Common Stock Stock Performance

CHRN stock opened at $20.42 on Friday. The business has a fifty day moving average price of $21.48 and a 200 day moving average price of $17.11. ChronoScale Corporation Common Stock has a fifty-two week low of $3.50 and a fifty-two week high of $30.00. The stock has a market capitalization of $2.97 billion, a price-to-earnings ratio of -3.80 and a beta of 0.98. The company has a debt-to-equity ratio of 0.06, a current ratio of 0.51 and a quick ratio of 0.51.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($0.12) earnings per share (EPS) for the quarter. The business had revenue of $18.40 million during the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. Analysts expect that ChronoScale Corporation Common Stock will post -0.1 EPS for the current fiscal year.

Institutional Investors Weigh In On ChronoScale Corporation Common Stock

An institutional investor recently raised its position in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc increased its position in shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN) by 104.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,338 shares of the company’s stock after acquiring an additional 1,195 shares during the quarter. Roble Belko & Company Inc owned about 0.07% of ChronoScale Corporation Common Stock worth $25,000 at the end of the most recent quarter. Institutional investors own 6.42% of the company’s stock.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.